于建议内部重组完成后，预期本公司于华润圣火持有的权益将由约63.02%摊薄至约 39.90%，而华润圣火将仍为本公司的非全资附属公司。Chinare Pharma (03320) announced that on November 21, 2024, China Resources Sanjiu signed an equity transfer agreement with Kunyao...
Wisdom Financial News APP reported that Chinare Pharma (03320) announced that on November 21, 2024, China Resources Sanjiu and Kunyao entered into an equity transfer agreement. China Resources Sanjiu has conditionally agreed to sell, and Kunyao has conditionally agreed to acquire 51% equity interest in China Resources Shenghuo for a total consideration of RMB 1.791 billion (equivalent to approximately HKD 1.938 billion). It is expected that China Resources Sanjiu will use the proceeds from the sale of 51% equity interest in China Resources Shenghuo to supplement its operating capital.
China Resources Sanjiu is an indirect non-wholly-owned subsidiary of the Company, as of the date of this announcement, the Company holds approximately 63.02% equity interest. China Resources Sanjiu's shares are listed on the Shenzhen Stock Exchange (stock code: 000999). Kunyao is an indirect non-wholly-owned subsidiary of the Company, as of the date of this announcement, the Company holds approximately 28.05% equity interest. Kunyao's shares are listed on the Shanghai Stock Exchange (stock code: 600422).
Upon completion of the proposed internal restructuring, it is expected that the Company's equity interest in China Resources Shenghuo will be diluted from approximately 63.02% to approximately 39.90%, while China Resources Shenghuo will remain an indirect non-wholly-owned subsidiary of the Company.
The proposed internal restructuring will help to implement the Company's '14th Five-Year Plan' global strategy, optimize the industry chain layout, promote the high-quality development of the Sanqi industry chain, further enhance China Resources Sanjiu's influence in the Sanqi industry, and address the issue of competitive products between China Resources Shenghuo and Kunyao's Xuesaitong soft capsule products. The Company believes that the proposed internal restructuring will fully leverage the respective advantages of China Resources Sanjiu and Kunyao in terms of products, sales and distribution networks, brands, supply chains, etc., and create synergistic value. At the same time, it is expected that the proposed internal restructuring will help accelerate the integration of the Sanqi industry chain, establish industry benchmarks, further enhance the market influence of the Group's Sanqi products, and better promote the high-quality development of the traditional Chinese medicine industry chain represented by Sanqi products, laying a solid foundation for the overall performance growth of the Company.